Question 1

What is Norgine?

Accepted Answer

Norgine is a Entity.

Question 2

How often does Norgine appear in global news?

Accepted Answer

Tracked across 7 news events drawn from 45 articles.

Question 3

When was Norgine first tracked by Ergen?

Accepted Answer

First tracked on Apr 07, 2026.

Question 4

When was Norgine last mentioned in news?

Accepted Answer

Last active on Aug 05, 2026.

Question 5

What is Norgine's current news sentiment?

Accepted Answer

Aggregate sentiment score: 14 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Norgine in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 7 events.

Question 7

What is the most recent event involving Norgine?

Accepted Answer

Norgine PEDMARQSI TGA Australia Approval (May 05, 2026, 6 articles).

Question 8

How did the "Norgine PEDMARQSI TGA Australia Approval" event impact Norgine?

Accepted Answer

Norgine received TGA registration for PEDMARQSI in Australia, expanding its market reach for this specialized medicine.

Question 9

How did the "Fennec Q2 2026 Results Announcement" event impact Norgine?

Accepted Answer

Norgine is Fennec's licensing partner for PEDMARQSI commercialization in Europe, U.K., Australia, and New Zealand. The event does not directly impact Norgine, but its partnership is part of Fennec's business update.

Question 10

How did the "Fennec Pharmaceuticals Q1 2026 Earnings" event impact Norgine?

Accepted Answer

Norgine has an exclusive licensing agreement with Fennec Pharmaceuticals to commercialize PEDMARQSI in Europe, U.K., Australia, and New Zealand.

Question 11

How did the "Fennec Pharmaceuticals Q1 2026 Earnings" event impact Norgine?

Accepted Answer

Norgine is the exclusive licensing partner for Fennec Pharmaceuticals' product PEDMARQSI in Europe, the UK, Australia, and New Zealand, contributing to the global commercialization of the drug.

Question 12

How did the "Fennec PEDMARK Study Expansion" event impact Norgine?

Accepted Answer

Norgine has an exclusive licensing agreement with Fennec Pharmaceuticals to commercialize PEDMARQSI (PEDMARK) in Europe, U.K., Australia, and New Zealand.

Question 13

How did the "Fennec Pharmaceuticals grants employee stock options" event impact Norgine?

Accepted Answer

Norgine is mentioned as a commercialization partner for PEDMARQSI, providing context on Fennec Pharmaceuticals' broader business activities, though not directly impacted by this specific stock option grant.

Question 14

How did the "Fennec Pharmaceuticals grants employee stock options" event impact Norgine?

Accepted Answer

Norgine is mentioned as a partner commercializing PEDMARQSI in Europe, U.K., Australia, and New Zealand, indicating Fennec Pharmaceuticals' broader market strategy.

Question 15

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.